MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
NCRM Cancer Stem Cell Conference: Updated Program
Dear Cancer Center Members:
Starting this weekend, the Case Comprehensive Cancer Center and National Center for Regenerative Medicine (NCRM), with University Hospitals Case Medical Center and Cleveland Clinic, are hosting the Cancer Stem Cell Conference (CSC 2014), August 17-20, 2014 at the Cleveland Convention Center.
This four-day conference has already attracted an impressive array of attendees; so far we have over 250 registrants from 15 countries and 25 states.
Together with my fellow conference directors Jeremy Rich, Arnold Caplan, Huiping Liu, and Justin Lathia, we developed an exciting and comprehensive conference program. We are honored to present a distinguished panel of speakers from around the world to highlight the remarkable advances in tumor biology and therapy that derive from integrating stem cell biology into cancer models. The program includes discussions from partners at NIH, academic centers, and industry in numerous cancer types, to present the state of the field, initiate collaborations, and accelerate discovery.
I encourage you to view the updated program agenda, view the impressive group of presenters being brought together at this forum, and register to attend this inaugural Cancer Stem Cell Conference.
CASE CCC IN THE NEWS
Hudson Team, Community Runs to Support Coach, Cancer Research
Hudson Hub Times - Aug 10, 2014
The Hudson High School cross country team decided to do a community service project this summer and from that desire came the Caplin Run for Cancer 2K and 5K Aug. 6...The race was named for Hudson head boys cross country coach Dave Caplin, who has been at Hudson for six years...He has received treatment at both University Hospital and the Cleveland Clinic, following his primary physician, Dr. Julian Kim, who is currently the Chief Medical Officer at the UH Seidman Cancer Center and member of the Case Comprehensive Cancer Center. Kim has operated on Caplin 12 times, along with multiple rounds of radiation and chemotherapy. "I wouldn't be here today without Kim and his staff," Caplin said. "When you are a cancer patient, it's frightening...but they are patient-friendly."
Experiment at Fred Hutch Raises Hopes in Battling Brain Tumors
Seattle Times - Aug 8, 2014
A gene-therapy experiment at Fred Hutchinson Cancer Research Center only involved a handful of brain-tumor patients, and on average, extended their lives by months, not years. .."I think this is actually one of those proof-of-concept milestones," said Dr. Stanton Gerson, director of the Case Comprehensive Cancer Center at Case Western Reserve University in Cleveland, who was not involved in the study. "This is the very first clinical validation that all that science made sense."
Benefits Add Up for Regular Aspirin Use
MedPage Today - Aug 4, 2014
Average-risk adults in the general population who used aspirin regularly for at least 5 years had a lower risk of cancer, myocardial infarction (MI), stroke, and premature death, according to a comprehensive review of potential benefits and harms..."What's clear from this compilation of studies ... is there is a very consistent finding, that regular use of aspirin over a period of years will reduce the risk of various types of cancer, including colorectal cancer, perhaps the most prominent to benefit," said Neal Meropol, MD, of University Hospitals Case Medical Center and Associate Director for Clinical Research at the Case Comprehensive Cancer Center in Cleveland.
Blocking Brain Tumors' Energy Supply
Lerner Research Institute Notations - Aug 2014
Brain tumor cells use glucose as their main energy source, but glucose reserves in the brain are very limited. Recent research from the laboratory of Jeremy Rich, MD, Chair of the Department of Stem Cell Biology and Regenerative Medicine and member of the Case Comprehensive Cancer Center, showed that early brain tumor cells adapt to this shortage of glucose by hijacking a glucose transporter protein called GLUT3. GLUT3 normally delivers glucose to healthy brain cells, but when used by brain tumor cells, it helps cancer grow and thrive. Dr. Rich recently received a $1.7 million, five-year R01 grant from the National Institute of Neurological Disorders and Stroke/National Institutes of Health to further study the GLUT3 pathway in brain cancer.
The Prostatome – A Novel Prostate Atlas Combining Anatomic and Disease Pathology Data Founded
Labmedica - Jul 23, 2014
Scientists have succeeded in fusing prostate cancer pathology data with anatomical magnetic resonance imaging (MRI) data to create the foundation of a first-of-its-kind prostate atlas for prostate cancer. A team of scientists and clinicians, led by Anant Madabhushi, professor of biomedical engineering and director of the Center of Computational Imaging and Personalized Diagnostics (CCIPD), and member of the Case Comprehensive Cancer Center at Case Western Reserve University, developed a novel framework, the anatomically constrained registration (AnCoR) scheme, and applied it to perform the fusion of initial data sets for creating the new prostate cancer (PrCa) "prostatome" atlas. The methods developed in the study can now be applied with a larger sample size data set to create a more fully developed atlas, which will allow for highly accurate identification of the MRI signatures associated with PrCa extent and aggressiveness.
RESEARCH HIGHLIGHTS/MEMBER NEWS
DiFeo and Steinmetz Recognized as "40 Under 40"
Cancer Center members Analisa DiFeo, PhD, Assistant Professor of General Medicine Sciences-Oncology at CWRU, and Nicole Steinmetz, PhD, Assistant Professor of Biomedical Engineering at CWRU, were nominated for the 2014 Crain's 40 Under 40 for their professional success and civic contributions. Both will be honored at a party in October.
PILOT PROJECT GRANTS: American Cancer Society IRG Awards
The Case Comprehensive Cancer Center, with funds from its American Cancer Society Institutional Research Grant (IRG), will provide seed money to foster cancer research by junior faculty who have no current national grant support of their own. Investigators in the CWRU School of Medicine and Cleveland Clinic Lerner College of Medicine as well as in other schools and colleges in the University are eligible. Grants, not to exceed $30,000, will be awarded to investigators who intend to gather preliminary data to be used in seeking future and independently funded programs.
IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (assistant professor or equivalent). Applicants for the pilot project grants should be within six years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but cannot currently hold such a grant. Recipients of IRG pilot project grants must be, at the time of the application, citizens or noncitizen nationals of the United States or its possessions and territories, or must have been lawfully admitted to the United States for permanent residence at the time of application.
LOI Deadline: August 15
Application Deadline: August 27
American Association for Cancer Research
The American Association for Cancer Research (AACR) is accepting applications for the following opportunities:
AACR Team Science Award
Deadline: September 3
AACR-CRI Lloyd J. Old Award in Cancer Immunology
Deadline: September 3
Pezcoller Foundation-AACR International Award for Cancer Research
Deadline: September 10
AACR Princess Takamatsu Memorial Lectureship
Deadline: September 17
AACR Award for Lifetime Achievement in Cancer Research
Deadline: September 24
AACR Award for Outstanding Achievement in Cancer Research
Deadline: October 1
AACR G.H.A. Clowes Memorial Award
Deadline: October 1
AACR Richard and Hinda Rosenthal Memorial Award
Deadline: October 8
AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
Deadline: October 15
AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship
Deadline: October 15
AACR Award for Outstanding Achievement in Chemistry in Cancer Research
Deadline: October 15
Szent-Györgyi Prize Nominations
The National Foundation for Cancer Research is accepting nominations for the Szent-Györgyi Prize. Nominations for the Prize may be made by individuals from the research community, industry, government, or other organizations who are sufficiently familiar with the research accomplishments and contributions of the nominee. Self-nominations will not be accepted.
Candidates will be reviewed and evaluated based on the following criteria: 1) Seminal discovery or a body of work that has resulted in, or led toward, notable contributions to cancer prevention, diagnosis, or treatment; and 2) The discovery has had a lasting impact on the cancer field with a high direct impact of saving people's lives
Deadline: September 30
PREVIOUSLY ANNOUNCED OPPORTUNITIES
NIH BULLETIN – Notices and Funding Opportunities
Revised Policy: Descriptions on the Use of Individual Development Plans (IDPs) for Graduate Students and Postdoctoral Researchers Required in Annual Progress Reports beginning October 1, 2014 (NOT-OD-14-113)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.